Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
17.82
+0.78 (4.58%)
At close: Dec 19, 2025, 4:00 PM EST
17.81
-0.01 (-0.06%)
After-hours: Dec 19, 2025, 7:59 PM EST
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
13.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | 49.46K | 6.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SMMT News
- 14 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying - Seeking Alpha
- 4 weeks ago - Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Business Wire
- 6 weeks ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire